The Association between Biomarker Profiles, Etiology of Chronic Kidney Disease, and Mortality

American Journal of Nephrology

Volumn 45, Issue 3, 2017, Pages 226-234

  Langsford, David ^a   Tang, Mila ^b   Cheikh Hassan, Hicham I ^a   Djurdjev, Ognjenka ^b,c   Sood, Manish M ^d   Levin, Adeera ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Provincial Renal Agency   (Canada)

^c CanPREDDICT Investigators   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

25 Hydroxylvitamin D; Asymmetric dimethylarginine; Chronic kidney disease; Cystatin C; Diabetes; Fibroblast growth factor 23; High sensitivity C reactive protein; Interleukin 6; Mortality; N terminal pro brain natriuretic peptide; Transforming growth factor beta; Troponin I

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CYSTATIN C; FIBROBLAST GROWTH FACTOR 23; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; TRANSFORMING GROWTH FACTOR BETA; TROPONIN I; PEPTIDE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION AND FOLLOW UP; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; KAPLAN MEIER METHOD; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; BLOOD; CHEMISTRY; FOLLOW UP; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; BIOMARKERS; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 85011693180     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000454991     Document Type: Article

References (34)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;(suppl 3):1-150.
2. Haynes R, Staplin N, Emberson J, et al: Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the study of heart and renal protection (SHARP). Am J Kidney Dis 2014; 64: 40-48.
3. Sud M, Tangri N, Levin A, et al: CKD stage at nephrology referral and factors influencing the risks of ESRD and death. Am J Kidney Dis 2014; 63: 928-936.
4. Landray MJ, Emberson JR, Blackwell L, et al: Prediction of ESRD and death among people with CKD: the chronic renal impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 2010; 56: 1082-1094.
5. McMurray JJ, Uno H, Jarolim P, et al: Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the trial to reduce cardiovascular events with Aranesp (darbepoetin-alfa) therapy (TREAT). Am Heart J 2011; 162: 748-755. e3.
6. Desai AS, Toto R, Jarolim P, et al: Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 2011; 58: 717-728.
7. Vickery S, Webb MC, Price CP, et al: Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population. Nephrol Dial Transplant 2008; 23: 3546-3553.
8. Michos ED, Wilson LM, Yeh HC, et al: Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med 2014; 161: 491-501.
9. Gutierrez OM, Januzzi JL, Isakova T, et al: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
10. Bouma-de Krijger A, Bots ML, Vervloet MG, et al: Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. Nephrol Dial Transplant 2014; 29: 88-97.
11. Kendrick J, Cheung AK, Kaufman JS, et al: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922.
12. Kovesdy CP, Quarles LD: The role of fibroblast growth factor-23 in cardiorenal syndrome. Nephron Clin Pract 2013; 123: 194-201.
13. Arnlov J, Carlsson AC, Sundstrom J, et al: Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013; 8: 781-786.
14. Smith K, deFilippi C, Isakova T, et al: Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. Am J Kidney Dis 2013; 61: 67-73.
15. Barreto DV, Barreto FC, Liabeuf S, et al: Plasma interleukin-6 is independently associated with mortality in both hemodialysis and predialysis patients with chronic kidney disease. Kidney Int 2010; 77: 550-556.
16. Schwedhelm E, Boger RH: The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 2011; 7: 275-285.
17. Caplin B, Leiper J: Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? Arterioscler Thromb Vasc Biol 2012; 32: 1343-1353.
18. Charytan DM, Padera R, Helfand AM, et al: Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. Int J Cardiol 2014; 176: 99-109.
19. Lu TM, Chung MY, Lin CC, et al: Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1566-1572.
20. Ravani P, Tripepi G, Malberti F, et al: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455.
21. Young JM, Terrin N, Wang X, et al: Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1115-1120.
22. Raptis V, Georgianos PI, Sarafidis PA, et al: Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease. Kidney Blood Press Res 2013; 38: 72-82.
23. Boger RH, Sullivan LM, Schwedhelm E, et al: Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119: 1592-1600.
24. Redondo S, Navarro-Dorado J, Ramajo M, et al: The complex regulation of TGF-β in cardiovascular disease. Vasc Health Risk Manag 2012; 8: 533-539.
25. Levin A, Rigatto C, Barrett B, et al; CanPREDDICT Investigators: Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant 2014; 29: 1037-1104.
26. Levin A, Rigatto C, Brendan B, et al: Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). BMC Nephrol 2013; 14: 121.
27. Steyerberg EW: Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. New York, Springer, 2009.
28. Packham DK, Alves TP, Dwyer JP, et al: Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 2012; 59: 75-83.
29. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al: Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352.
30. Tancredi M, Rosengren A, Svensson AM, et al: Excess mortality among persons with type 2 diabetes. N Engl J Med 2015; 373: 1720-1732.
31. Lajer M, Tarnow L, Jorsal A, et al: Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008; 31: 747-752.
32. Troughton R, Michael Felker G, Januzzi JL Jr: Natriuretic peptide-guided heart failure management. Eur Heart J 2014; 35: 16-24.
33. Hung SC, Kuo KL, Peng CH, et al: Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int 2014; 85: 703-709.
34. Eckardt KU, Gillespie IA, Kronenberg F, et al: High cardiovascular event rates occur within the first weeks of starting hemodialysis. Kidney Int 2015; 88: 1117-1125.